Sunitinib

The antiangiogenic effects and beyond

Zhonglin Hao, Ibrahim Sadek

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

As a multitargeted kinase inhibitor, sunitinib has carved its way into demonstrating itself as a most effective tyrosine kinase inhibitor in the treatment of metastatic renal cell carcinoma. Mechanistically, sunitinib inhibits multiple receptor tyrosine kinases, especially those involved in angiogenesis, that is, vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and proto-oncogene cKIT. Sunitinib has also been implicated in enhancing cancer invasiveness and metastasis. Mechanisms of resistance are poorly understood, but both intrinsic and acquired mechanisms are thought to be involved. While the side effects are manageable, sunitinib, like many other tyrosine kinase inhibitors, can be associated with serious toxicities that require careful management including frequent dose reductions. Although still in the early stage, emerging evidence points to an immunomodulatory role for sunitinib. It is also likely to contribute to the overall outcomes, especially those seen in metastatic renal cell carcinoma, and such effects are thought to be mediated by the proto-oncogene cKIT receptor. Combination with other modalities such as stereotactic body radiation therapy, therapeutic vaccines, and checkpoint inhibitors is being pursued for improved efficacy.

Original languageEnglish (US)
Pages (from-to)5495-5505
Number of pages11
JournalOncoTargets and Therapy
Volume9
DOIs
StatePublished - Sep 8 2016

Fingerprint

Proto-Oncogenes
Renal Cell Carcinoma
Protein-Tyrosine Kinases
Platelet-Derived Growth Factor Receptors
Vascular Endothelial Growth Factor Receptor
Receptor Protein-Tyrosine Kinases
Phosphotransferases
Radiotherapy
Vaccines
sunitinib
Neoplasm Metastasis
Therapeutics
Neoplasms

Keywords

  • Angiogenesis
  • Cancer
  • MDSC
  • Sunitinib

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Sunitinib : The antiangiogenic effects and beyond. / Hao, Zhonglin; Sadek, Ibrahim.

In: OncoTargets and Therapy, Vol. 9, 08.09.2016, p. 5495-5505.

Research output: Contribution to journalReview article

Hao, Zhonglin ; Sadek, Ibrahim. / Sunitinib : The antiangiogenic effects and beyond. In: OncoTargets and Therapy. 2016 ; Vol. 9. pp. 5495-5505.
@article{cd12daa39a7a43d684dc7f8834a560b0,
title = "Sunitinib: The antiangiogenic effects and beyond",
abstract = "As a multitargeted kinase inhibitor, sunitinib has carved its way into demonstrating itself as a most effective tyrosine kinase inhibitor in the treatment of metastatic renal cell carcinoma. Mechanistically, sunitinib inhibits multiple receptor tyrosine kinases, especially those involved in angiogenesis, that is, vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and proto-oncogene cKIT. Sunitinib has also been implicated in enhancing cancer invasiveness and metastasis. Mechanisms of resistance are poorly understood, but both intrinsic and acquired mechanisms are thought to be involved. While the side effects are manageable, sunitinib, like many other tyrosine kinase inhibitors, can be associated with serious toxicities that require careful management including frequent dose reductions. Although still in the early stage, emerging evidence points to an immunomodulatory role for sunitinib. It is also likely to contribute to the overall outcomes, especially those seen in metastatic renal cell carcinoma, and such effects are thought to be mediated by the proto-oncogene cKIT receptor. Combination with other modalities such as stereotactic body radiation therapy, therapeutic vaccines, and checkpoint inhibitors is being pursued for improved efficacy.",
keywords = "Angiogenesis, Cancer, MDSC, Sunitinib",
author = "Zhonglin Hao and Ibrahim Sadek",
year = "2016",
month = "9",
day = "8",
doi = "10.2147/OTT.S112242",
language = "English (US)",
volume = "9",
pages = "5495--5505",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Sunitinib

T2 - The antiangiogenic effects and beyond

AU - Hao, Zhonglin

AU - Sadek, Ibrahim

PY - 2016/9/8

Y1 - 2016/9/8

N2 - As a multitargeted kinase inhibitor, sunitinib has carved its way into demonstrating itself as a most effective tyrosine kinase inhibitor in the treatment of metastatic renal cell carcinoma. Mechanistically, sunitinib inhibits multiple receptor tyrosine kinases, especially those involved in angiogenesis, that is, vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and proto-oncogene cKIT. Sunitinib has also been implicated in enhancing cancer invasiveness and metastasis. Mechanisms of resistance are poorly understood, but both intrinsic and acquired mechanisms are thought to be involved. While the side effects are manageable, sunitinib, like many other tyrosine kinase inhibitors, can be associated with serious toxicities that require careful management including frequent dose reductions. Although still in the early stage, emerging evidence points to an immunomodulatory role for sunitinib. It is also likely to contribute to the overall outcomes, especially those seen in metastatic renal cell carcinoma, and such effects are thought to be mediated by the proto-oncogene cKIT receptor. Combination with other modalities such as stereotactic body radiation therapy, therapeutic vaccines, and checkpoint inhibitors is being pursued for improved efficacy.

AB - As a multitargeted kinase inhibitor, sunitinib has carved its way into demonstrating itself as a most effective tyrosine kinase inhibitor in the treatment of metastatic renal cell carcinoma. Mechanistically, sunitinib inhibits multiple receptor tyrosine kinases, especially those involved in angiogenesis, that is, vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and proto-oncogene cKIT. Sunitinib has also been implicated in enhancing cancer invasiveness and metastasis. Mechanisms of resistance are poorly understood, but both intrinsic and acquired mechanisms are thought to be involved. While the side effects are manageable, sunitinib, like many other tyrosine kinase inhibitors, can be associated with serious toxicities that require careful management including frequent dose reductions. Although still in the early stage, emerging evidence points to an immunomodulatory role for sunitinib. It is also likely to contribute to the overall outcomes, especially those seen in metastatic renal cell carcinoma, and such effects are thought to be mediated by the proto-oncogene cKIT receptor. Combination with other modalities such as stereotactic body radiation therapy, therapeutic vaccines, and checkpoint inhibitors is being pursued for improved efficacy.

KW - Angiogenesis

KW - Cancer

KW - MDSC

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84988728255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988728255&partnerID=8YFLogxK

U2 - 10.2147/OTT.S112242

DO - 10.2147/OTT.S112242

M3 - Review article

VL - 9

SP - 5495

EP - 5505

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -